Not only is today is World COPD Day, but November is also COPD awareness month. Also known as chronic obstructive pulmonary disease, COPD is a group of lung conditions which have no cure and are characterised by a narrowing of the airways. According to the British Lung Foundation, COPD affects 2% of the UK population, which equates to a patient population of 1.2 million, and this is just based on patients with a diagnosis.


Living with COPD can make even the simplest task exhausting. Current treatment focuses on alleviating symptoms, but cannot stop disease progression. If inhalers and oxygen do not help, surgery or a lung transplant could be a final option.

However, drug developers are working to change this, and improve the lives of patients affected by COPD. As of today, there are 741 active clinical studies targeting COPD, and Simbec-Orion is proud to be part of the journey to a better quality of life for patients suffering from this disease.[2]

Simbec-Orion have delivered COPD studies om initial First-in-Human to pivotal phase III studies, and in addition to our study experience, we are also one of the few CROs to have a full scintigraphy suite, offering a deeper level of insight in respiratory studies.

If you are looking to find out more about our respiratory expertise, please get in touch at and see how we could be the right fit for your clinical trial needs.





[1] British Lung Foundation

[2] In a search of Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies on